BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

12 May 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

10 May 2022 15:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

05 May 2022 06:30:02 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

03 Apr 2022 07:36:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo

28 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

11 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)

08 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

24 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

27 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

13 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study

27 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

19 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing

18 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 Jun 2021 15:35:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

01 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

28 May 2021 13:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 May 2021 15:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

14 May 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update

06 May 2021 06:30:01 By Nasdaq GlobeNewswire